In conclusion, a biomarker score combining the levels of NKA and methylated HOXA9 after the first cycle of treatment can be used to stratify the prognosis of patients with NSCLC treated with PD-1/PD-L1 inhibitors. Here, HOXA9 is linked to non-small cell lung carcinoma.